IE
RNXT icon

Israel Englander’s RenovoRx RNXT Stock Holding History

Israel Englander’s Portfolio RNXT Stock Details RNXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-76,814
Closed -$99.1K – 6322
2024
Q4 		$99.1K Sell
76,814
-5,539
-7% -$6.3K ﹤0.01% 5478
2024
Q3 		$87.3K Sell
82,353
-3,963
-5% -$4.44K ﹤0.01% 5607
2024
Q2 		$97.5K Buy
+86,316
New +$106K ﹤0.01% 5313

Other funds holding RNXT

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return

Israel Englander's RNXT Position: Q1 2025 in Review

Israel Englander sold out of RenovoRx (RNXT) in Q1 2025, closing a stake of 76,814 shares — an estimated $99.1K sold.

Israel Englander first reported a position in RNXT in Q2 2024 and held it in 3 quarters. The position peaked at $99.1K in Q4 2024. 27 funds tracked by Wall St. Rank hold RNXT as of Q1 2025.

  • Israel Englander reported no remaining RenovoRx position as of Q1 2025 after selling out during the quarter.
  • Israel Englander sold 76,814 RenovoRx shares in Q1 2025, an estimated $99.1K.
  • Israel Englander first reported a position in RenovoRx in Q2 2024 and held it in 3 quarters.
  • Israel Englander's RenovoRx position peaked at $99.1K in Q4 2024.
  • 27 funds tracked by Wall St. Rank held RenovoRx as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.